<DOC>
	<DOC>NCT00944450</DOC>
	<brief_summary>This study will establish that the MK0431 100 mg anhydrous formulation tablets are bioequivalent to the MK0431 100 mg monohydrate final market image (FMI) tablets.</brief_summary>
	<brief_title>Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Subject is in good health Female subjects must have a negative pregnancy test Subject is within 30% of ideal body weight Subject does not smoke Subject agrees to follow the study guidelines Subject has a history of any illness that might confound the results of the study or make participation unsafe for the subject Subject has a history of hypoglycemia Subject has a history of any hepatic disease Subject is taking any oral, parenteral, topical or implantable contraceptives</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>